Alembic Pharmaceuticals Limited (BOM:533573)
India
· Delayed Price · Currency is INR 899.90
-2.30 (-0.25%)
At close: Dec 5, 2025
Alembic Pharmaceuticals Revenue
Alembic Pharmaceuticals had revenue of 19.10B INR in the quarter ending September 30, 2025, with 15.91% growth. This brings the company's revenue in the last twelve months to 70.83B, up 11.42% year-over-year. In the fiscal year ending March 31, 2025, Alembic Pharmaceuticals had annual revenue of 66.72B with 7.12% growth.
Revenue (ttm)
70.83B
Revenue Growth
+11.42%
P/S Ratio
2.50
Revenue / Employee
4.27M
Employees
16,571
Market Cap
176.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 66.72B | 4.43B | 7.12% |
| Mar 31, 2024 | 62.29B | 5.76B | 10.19% |
| Mar 31, 2023 | 56.53B | 3.47B | 6.54% |
| Mar 31, 2022 | 53.06B | -873.40M | -1.62% |
| Mar 31, 2021 | 53.93B | 7.87B | 17.10% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,996.29B |
| HDFC Bank | 2,683.70B |
| Bharti Airtel | 1,946.14B |
| Tata Consultancy Services | 2,576.88B |
| ICICI Bank | 1,909.34B |
| State Bank of India | 3,571.95B |
| Infosys | 1,748.84B |
| Bajaj Finance | 406.39B |
Alembic Pharmaceuticals News
- 19 days ago - Alembic Pharma shares rise over 2% after USFDA nod for Diltiazem Hydrochloride Tablets - Business Upturn
- 21 days ago - Alembic Pharma gets USFDA final nod for Diltiazem Hydrochloride Tablets - Business Upturn
- 23 days ago - Alembic Pharma secures final USFDA approval for Dexlansoprazole DR capsules - Business Upturn
- 4 weeks ago - Alembic Pharmaceuticals receives USFDA final approval for Dasatinib Tablets across six strengths - Business Upturn
- 4 weeks ago - Q2 2026 Alembic Pharmaceuticals Ltd Earnings Call Transcript - GuruFocus
- 4 weeks ago - Alembic Pharma shares rally sharply over 6% as Q2 net profit jumps 21% YoY to Rs 185 crore, revenue up 16% - Business Upturn
- 5 weeks ago - Alembic Pharmaceuticals gets USFDA final approval for Ticagrelor Tablets 60 mg; targets $236 million market - Business Upturn
- 3 months ago - Alembic Pharma receives USFDA final approval for Phytonadione Injectable Emulsion USP - Business Upturn